Skip to main content
Premium Trial:

Request an Annual Quote

Lion s Revenues Up 161 Percent, R&D Costs up 139 Percent

NEW YORK, Feb 7 – Lion bioscience said Wednesday its fiscal third quarter 2001 revenues more than doubled to 7.7 million euros ($7.1 million), compared with 2.9 million euros in the year ago period, as research and development as well as licensing fees increased.

Revenues from research and development fees shot up 161 percent to 4.7 million euros, while licensing fees increased 38 percent to 2.9 million euros.

At the same time, however, a 139 percent increase in R&D costs contributed to higher losses from operations. from 3.0 to 4.3 milion Euros.

During the quarter, Lion formed alliances with Celera and Bayer, and acquired Trega Biosciences, based in San Diego.

Celera now uses LION's SRS technology as the base technology for its Celera Discovery System. With Bayer, Lion expanded into the field of pharmacophore informatics, and the merger with Trega combined the two companies’ drug discovery and data analysis capabilities.

Net losses for the third quarter FY 2001 dropped to 2.2 from 3.0 million Euros in the year-ago quarter.

In January, Lion released ArrayScout 2.0, an updated version of it gene expression data analysis system.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.